Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
A MACHINE-LEARNING CLASSIFIER FOR EPISODIC MIGRAINE BASED ON VISUAL EVOKED GAMMA BAND ACTIVITY
Ort / Verlag
Blackwell Science
Erscheinungsjahr
2016
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
Introduction: Objective and reliable biomarkers of
migraine may be of interest for diagnosis and research
purposes. Neuroimaging-based machine-learning classifiers
are promising but hampered by availability and cost issues.
Conversely, evoked potential are of easy access and affordable.
They have provided increasing evidence that sensory
information processing is impaired in migraine. We have
used gamma band oscillations (GBOs) of visual evoked
potentials (VEPs) to compute a machine-learning neural
network classifier in episodic migraine.
Materials and methods: We analyzed GBOs from VEPs
(6x100 responses). Recordings were performed in two
matched samples: a training sample composed of 43
migraine patients (EM) and 20 healthy volunteers (HV)
and a validating sample of 18 EM and 10 HV. A logistic
regression model of the training sample was performed
to evaluate the relevance of the predictor variables. Ten
neural networks were automatically generated based on
late component frequency, n3-p4 and p4-n4 slopes, 1st
block n1-p2 amplitude and age.
Results: The logistic regression model of the training
sample reached a significant classification rate of 79%
(EM: 88%; HV: 60%, p¼0.002). The best neural network
was able to classify the groups with an accuracy of 73% in
the training phase and 89% in the subsequent validation
(success rate HV: 90%; EM: 88%). The mean global accuracy
within the training and validating samples were 69%
(63–78%) and 84% (82–89%).
Conclusions: This machine-learning neural network classifier
based on visual GBOs provides an accurate and costefficient
tool for objective migraine diagnosis. Further
training and validation studies with new cohorts are
warranted